BPC-157

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein BPC. It has been characterized almost exclusively in rodent models of tendon, ligament, muscle and gastrointestinal injury. There is no completed Phase II or III clinical program, and published human safety data are limited.

Reported mechanisms center on modulation of the nitric oxide system and upregulation of VEGFR2 signaling, with downstream activation of the Akt-eNOS pathway and increased angiogenesis at the injury site. Rodent research also describes increased fibroblast migration and collagen organization, and interaction with the dopaminergic and serotonergic systems in models of gut-brain signaling.

Store the sealed lyophilized vial at 2-8 °C, protected from light; brief exposure to room temperature during shipping is generally tolerated. Refrigerate after reconstitution at 2-8 °C and use within the period supported by stability data for the substance (typically 2-4 weeks). Avoid repeated freeze-thaw cycles: each cycle increases the risk of aggregation and hydrolysis of the peptide bond. Do not shake the vial; swirl gently and direct the liquid stream against the glass wall rather than at the powder cake.

• Sealed lyophilized vial, stored as supplied
• Bacteriostatic water (0.9% benzyl alcohol) for reconstitution
• Insulin syringes (29-31G, 0.5 mL / 100 units)
• Reconstitution syringe (1-3 mL, 21-23G needle)
• 70% isopropyl alcohol swabs
• Sharps container for used needles
• Labels and a logbook for batch, date and volume

Animal studies report accelerated closure in tendon and muscle transection models, protection against NSAID-induced gastric injury, and attenuation of colitis markers. Reported adverse effects in rodents at multiples of the modeled dose are minimal, but the absence of controlled human toxicology means adverse effect profiles, immunogenicity and long-term risk remain unknown. Injection-site irritation and transient lightheadedness are the most commonly reported anecdotal findings.

Wash your hands, then disinfect the vial septum and the injection site with 70% isopropyl alcohol and allow both to air dry. Draw up the intended volume, remove air bubbles and pinch a subcutaneous skin fold. Insert at a 45-90° angle depending on fat thickness, aspiration is not required for subcutaneous administration, and inject slowly. Withdraw the needle, apply light pressure and discard the needle in a sharps container. Rotate injection sites systematically (abdominal quadrants, flanks, thighs) to prevent lipohypertrophy and local irritation.

Peptide research protocols are studied against a background of adequate protein intake (approximately 1.6-2.2 g/kg/day in the training literature), consistent sleep of 7-9 hours, and controlled training load. Sleep deprivation and chronic psychological stress both dampen growth hormone pulsatility and disrupt tissue remodeling, complicating the interpretation of any observed effect. Alcohol, smoking and large caloric deficits are likewise documented modifiers of recovery outcomes.

1. Sikiric P. et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des, 2011.
2. Chang C.H. et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol, 2011.
3. Hsieh M.J. et al. Therapeutic potential of BPC 157 in vascular healing via VEGFR2-Akt-eNOS. J Mol Med, 2017.